3,079 results
Search Results
2. Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis
3. Application of the Convection–Dispersion Equation to Modelling Oral Drug Absorption
4. Optimal treatments for photodynamic therapy
5. Individualization of theophylline infusion rate on the basis of a nonlinear compartmental pharmacokinetic model
6. Update on 1-benzylpiperazine (BZP) party pills
7. PLGA 50:50 nanoparticles of paclitaxel: Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation
8. HPLC Determination of Gemifloxacin in Different Tissues of Rats Under Normobaric and Hyperbaric Exposure
9. Klinisch relevante pharmakokinetische Arzneimittelinteraktionen in der Intensivmedizin: Eine Übersicht
10. Klinisch relevante pharmakokinetische Arzneimittelinteraktionen in der Intensivmedizin: Eine Übersicht
11. High-performance liquid chromatography with photodiode array detection for determination of nobiletin content in the brain and serum of mice administrated the natural compound
12. Pharmacokinetics of levodopa
13. Bioactivity and pharmacokinetics of two human serum albumin–thymosin α1-fusion proteins, rHSA-Tα1 and rHSA-L-Tα1, expressed in recombinant Pichia pastoris
14. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus
15. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation
16. Clinical pharmacology and pharmacogenetics of thiopurines
17. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia
18. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma
19. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
20. Ocular penetration of caspofungin in a rabbit uveitis model
21. Pharmacokinetic studies of flumecinol in man and dog
22. Rifampicin in plasma and pleural fluid after single oral doses
23. Pharmacokinetics — Uses and abuses
24. Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay
25. Ultraschallkontrastmittel: Substanzklassen, Pharmakokinetik, klinische Anwendungen, Sicherheitsaspekte
26. Regulatory aspects of pharmacogenetics and pharmacogenomics
27. 99mTc-MAG3: Review of pharmacokinetics, clinical application to renal diseases and quantification of renal function
28. Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists
29. Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses
30. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol
31. Parametric imaging of patient pharmacokinetics
32. Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?
33. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry
34. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations
35. Pharmacokinetics of endogenous substances: Some problems and some solutions
36. Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics
37. Pharmacokinetic and pharmacodynamic data and models in clinical trials
38. A physiologically based mathematical model for the human inhalation pharmacokinetics of 1,1,2-trichloro-1,2,2-trifluoroethane
39. The normalization of total clearances for intravenous injection drugs
40. Letters to the editors Nonlinear kinetics of nortriptyline in every day practice*
41. Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma
42. Evaluation of paraquat concentrations in paraquat poisoning
43. Pharmacokinetics of mestranol in man in relation to its oestrogenic activity
44. Pharmacodynamics and pharmacokinetics of furosemide combinations with potassium-retaining and thiazide-like diuretics: Clearance and micropuncture studies
45. Comparative pharmacokinetic analysis of amoxycillin using open two and three-compartment models
46. Tolerability and pharmacokinetics of L-648,051. A leukotriene D4-receptor antagonist, in healthy volunteers
47. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam
48. Sulfadimethoxine — bucolome interaction in rabbits : role of N4-acetylsulfadimethoxine, a major metabolite of sulfadimethoxine
49. Pharmacokinetics and quantitative characterization of cefotiam excretion after intravenous administration to patients after cholecystectomy
50. Pharmacokinetics of spironolactone in man
51. Disposition of dibekacin in patients undergoing haemodialysis
52. Interindividual differences in chlorthalidone concentration in plasma and red cells of man after single and multiple doses
53. Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency
54. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin: 1. Dose-dependent tissue distribution and induction of hepatic ethoxyresorufin O-deethylase in rats following a single injection
55. Effect of enterohepatic circulation on the pharmacokinetics of spironolactone in man
56. Evaluation of a micromethod for determination of antibiotic concentrations in plasma
57. Biochemistry and pharmacology of the crotoxin complex: II. Possible interrelationships between toxicity and organ distribution of phospholipase A, crotapotin and their combination
58. Prenatal exposure to escitalopram and/or stress in rats: A prenatal stress model of maternal depression and its treatment
59. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers
60. Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry
61. Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study
62. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
63. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
64. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection
65. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
66. Simultaneous Determination of α- and γ-Mangostins in Mouse Plasma by HPLC–MS/MS Method: Application to a Pharmacokinetic Study of Mangosteen Extract in Mouse
67. Hollow-Fiber-Based LPME as a Reliable Sampling Method for Gas-Chromatographic Determination of Pharmacokinetic Parameters of Valproic Acid in Rat Plasma
68. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers
69. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats
70. Influence of Bariatric Surgery on the Use and Pharmacokinetics of Some Major Drug Classes
71. Correlation of contrast agent kinetics between iodinated contrast-enhanced spectral tomosynthesis and gadolinium-enhanced MRI of breast lesions
72. Pharmacokinetics, Tissue Distribution and Excretion of Recombinant Human Parathyroid Hormone 1–84 in Animals
73. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs
74. C max and t max verification using Fibonacci sequence and absorption rate
75. Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
76. Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution
77. Validated LC-ESI-MS/MS Method for the Quantitation of Neopanaxadiol: a Novel Neuroprotective Agent from Panax ginseng and Its Application to a Pharmacokinetic Study in Rat Plasma
78. Pharmakokinetische Parameter: Altersbedingte Änderungen und Einfluss auf die Therapiefähigkeit
79. A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
80. Simultaneous Quantification of Aliskiren, Valsartan and Sitagliptin by LC with Fluorescence Detection: Evidence of Pharmacokinetic Interaction in Rats
81. Pharmacokinetics of teduglutide in subjects with renal impairment
82. Therapeutic drug monitoring for tomorrow
83. Pharmacokinetics Study of Amoxycillin and Clavulanic acid (8:1)-A New Combination in Healthy Chinese Adult Male Volunteers Using the LC–MS/MS Method
84. Correlations between the selected parameters of the chemical structure of drugs and between-subject variability in area under the curve
85. A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens
86. Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers
87. Evaluation of chemically diverse 5-HT2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles
88. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects
89. CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects
90. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers
91. A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors
92. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray
93. Medikamentöse Therapie bei Frauen – Was gilt es zu beachten?
94. Strategien zur Vermeidung von Antibiotikaresistenzen
95. Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing
96. Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation
97. Effects of pyridoxine on the intestinal absorption and pharmacokinetics of isoniazid in rats
98. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers
99. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis
100. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.